### Philippines

#### Tuberculosis profile

**Population 2017**
105 million

<table>
<thead>
<tr>
<th>Estimate</th>
<th>2017</th>
<th>Number (thousands)</th>
<th>Rate per 100,000 population</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mortality (excludes HIV+TB)</td>
<td>26</td>
<td>(23–31)</td>
<td>25</td>
</tr>
<tr>
<td>Mortality (HIV+TB only)</td>
<td>0.38</td>
<td>(0–3.3)</td>
<td>0.36</td>
</tr>
<tr>
<td>Incidence (includes HIV+TB)</td>
<td>581</td>
<td>(326–909)</td>
<td>554</td>
</tr>
<tr>
<td>Incidence (HIV+TB only)</td>
<td>7.1</td>
<td>(2.9–13)</td>
<td>6.7</td>
</tr>
<tr>
<td>Incidence (MDR/RR-TB)**</td>
<td>27</td>
<td>(12–47)</td>
<td>26</td>
</tr>
</tbody>
</table>

#### Estimated TB incidence by age and sex (thousands)*, 2017

<table>
<thead>
<tr>
<th>Age</th>
<th>Females</th>
<th>Males</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>0-14 years</td>
<td>34</td>
<td>(30–38)</td>
<td>139</td>
</tr>
<tr>
<td>&gt; 14 years</td>
<td>37</td>
<td>(33–42)</td>
<td>371</td>
</tr>
<tr>
<td>Total</td>
<td>71</td>
<td>(59–84)</td>
<td>510</td>
</tr>
</tbody>
</table>

#### Incidence

- **Total cases notified**
  - 328,773
- **Total new and relapse**
  - 317,266
- **-% tested with rapid diagnostics at time of diagnosis**
  - 26%
- **-% with known HIV status**
  - 24%
- **-% pulmonary**
  - 98%
- **-% bacteriologically confirmed among pulmonary**
  - 39%

#### Universal health coverage and social protection

- **TB treatment coverage (notified/estimated incidence), 2017**
  - 55% (35–97)
- **TB patients facing catastrophic total costs, 2017**
  - 35%
- **TB case fatality ratio (estimated mortality/estimated incidence), 2017**
  - 0.05 (0.03–0.08)

#### Drug-resistant TB care, 2017

- **Estimated MDR/RR-TB cases among notified pulmonary TB cases**
  - 20,000 (18,000–22,000)
- **Estimated % of TB cases with MDR/RR-TB**
  - 2.6% (1.9–3.4) 28% (27–28)
- **% notified tested for rifampicin resistance**
  - 19% 83% 93,058
- **MDR/RR-TB cases tested for resistance to second-line drugs**
  - 2,401
- **Laboratory-confirmed cases**
  - MDR/RR-TB: 6,438, XDR-TB: 15
- **Patients started on treatment ******
  - MDR/RR-TB: 5,623, XDR-TB: 16

#### Treatment success rate and cohort size

- **Treatment success rate (%)**
  - 91% 332,308
  - 80% 10,097
  - 82% 10,899
  - 54% 3,851
  - 33% 9

#### TB preventive treatment, 2017

- **% of HIV-positive people (newly enrolled in care) on preventive treatment**
  - 57%
- **% of children (aged < 5) household contacts of bacteriologically-confirmed TB cases on preventive treatment**
  - 12% (11–13)

#### TB financing, 2018

- **National TB budget (US$ millions)**
  - 160

**Ranges represent uncertainty intervals**

**MDR is TB resistant to rifampicin and isoniazid; RR is TB resistant to rifampicin**

**Includes cases with unknown previous TB treatment history**

**Includes patients diagnosed before 2017 and patients who were not laboratory-confirmed**

---

Data: www.who.int/tb/data

*Generated: 2018-10-31*